



June 2025

Dear Valued Client,

Effective July 7, 2025, ViroMed will transition to the Abbott Alinity s Anti-HCV II assay for screening all living and cadaveric donors. This new assay should enhance seroconversion sensitivity without compromising its high specificity.

The updated HCV test will be applied to all samples sent for anti-HCV testing, with no extra costs or changes to test numbers, specimen requirements or result delivery times. The implementation of this new assay will be noted in patient reports.

We appreciate the opportunity to serve your testing needs. Please contact ViroMed Account Management at 800-582-0077 or [ViroMed\\_Acctmgmt@labcorp.com](mailto:ViroMed_Acctmgmt@labcorp.com) if you have any questions.

Sincerely,

A handwritten signature in black ink that reads "Ajay Grover". The signature is written in a cursive, flowing style.

Ajay Grover, MS, PhD, BCMAS, HCLD (ABB)  
Laboratory Director  
ViroMed Laboratories